Bipolar Disorder Manic Depression Market

DelveInsight’s ‘Bipolar Disorder (Manic Depression) - Market Insights, Epidemiology, and Market Forecast—2030’ report delivers an in-depth understanding of the Bipolar Disorder (Manic Depression), historical and forecasted epidemiology as well as the Bipolar Disorder (Manic Depression) market trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.


The Bipolar Disorder (Manic Depression) market report provides current treatment practices, emerging drugs, Bipolar Disorder (Manic Depression) market share of the individual therapies, current and forecasted Bipolar Disorder (Manic Depression) market size from 2017 to 2030 segmented by seven major markets. The Report also covers current Bipolar Disorder (Manic Depression) treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.

Geography Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2017–2030

Bipolar Disorder (Manic Depression): Disease Understanding and Treatment Algorithm

Bipolar Disorder (Manic Depression) Overview

Bipolar disorder (BD), previously known as manic depressive illness or manic depression, is a mental disorder characterized by wide mood swings from high (manic) to low (depressed). In manic episodes, a person can be delighted, irritable, and there is a marked increase in activity level, whereas, in depressive episodes, someone might feel sad, indifferent, or hopeless, in combination with a deficient activity level. Hypomanic episodes are also seen in patients, and it is a less severe form of mania. It is divided mainly into four subtypes BD-I, BD-II, cyclothymic disorder, and BD not otherwise specified (BD-NOS); the classification is based on the characteristics of mood swings.


Specifically, the lows that a patient may be feeling, those moments of hopelessness, are the possible symptoms of the depressive moments associated with BD. Bipolar Disorder (Manic Depression) is a lifelong condition that creates unusual mood changes that can vary in length and severity. For people living with Bipolar Disorder (Manic Depression), there are three times as many depressive episodes as manic ones. Also, those episodes often last 50% longer.


The symptoms of Bipolar Disorder (Manic Depression) include feeling sad or anxious; restless; trouble concentrating or making decisions; trouble falling asleep, waking up too early, or sleeping too much; lack of interest; feeling hopeless or worthless, or thinking about death or suicide; unable to do even simple things, and talking very slowly, feeling like he/she has nothing to say, or forgetting a lot.


Bipolar Disorder (Manic Depression) Diagnosis

There is no test available for the diagnosis, a psychiatrist can diagnose it based on the patient’s history and symptoms. Bipolar Disorder (Manic Depression) is often misdiagnosed as unipolar depression as long as manic episodes do not appear. The diagnosis usually requires a physical examination, psychiatric assessment, mood charting, and the use of ICD-10 or DSM-5 criteria for bipolar episodes in BD. The differential diagnoses are major depression, anxiety disorders, ADHD, personality disorder, drug and alcohol misuse, schizophrenia, in addition to consequences of trauma/brain injury.


Bipolar Disorder (Manic Depression) Treatment

The goal of treatment is to achieve as high as possible a level of psychosocial function and health-related quality of life. The treatment has two phases, the acute phase, and the maintenance phase. Bipolar Disorder (Manic Depression) is highly recurrent, and sometimes medication needs to continue even if the patient feels well. The treatment has two phases: the acute phase and the maintenance phase. Acute-phase treatment is focused on the management of acute mood episodes, whereas maintenance-phase treatment is focused on preventing recurrences of acute episodes. Each phase is associated with specific treatment needs, and available pharmacotherapies have shown a difference in effectiveness according to the illness phase. The treatment of Bipolar Disorder (Manic Depression) includes mood stabilizers, antipsychotics, antidepressants, antianxiety medications, and psychotherapy.

Bipolar Disorder (Manic Depression) Epidemiology

The Bipolar Disorder (Manic Depression) epidemiology division provides insights about the historical and current Bipolar Disorder (Manic Depression) patient pool and forecasted trends for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.


Key Findings

  • In the year 2020, the total diagnosed prevalent case of Bipolar Disorder (Manic Depression) was 3,552,076 cases in the 7MM which are expected to grow during the study period, i.e., 2017–2030.
  • The disease epidemiology covered in the report provides historical as well as forecasted Bipolar Disorder (Manic Depression) epidemiology [segmented as Total Diagnosed Prevalent Cases of Bipolar Disorder (Manic Depression), Type-specific Diagnosed Prevalent Cases of Bipolar Disorder (Manic Depression), Severity-specific Diagnosed Prevalent Cases of Bipolar Disorder (Manic Depression), and Total Treated Cases of Bipolar Disorder (Manic Depression)] in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2017 to 2030.

Country Wise- Bipolar Disorder (Manic Depression) Epidemiology

Estimates show that the highest cases of Bipolar Disorder (Manic Depression) in the 7MM were in the United States, followed by Germany, Italy, the United Kingdom, France, Japan, and Spain in the year 2020.


  • In the United States, the total number of diagnosed prevalent cases of Bipolar Disorder (Manic Depression) was 2,401,287 cases in the year 2020 which are expected to grow during the study period, i.e., 2017–2030.
  • In the year 2020, the total diagnosed prevalent cases of Bipolar Disorder (Manic Depression) were 1,004,168 cases in EU-5 which are expected to grow during the study period, i.e., 2017–2030.
  • In Japan, the total number of diagnosed prevalent cases of Bipolar Disorder (Manic Depression) was 146,621 cases in the year 2020 which are expected to grow during the study period, i.e., 2017–2030.

Bipolar Disorder (Manic Depression) Drug Chapters

The drug chapter segment of the Bipolar Disorder (Manic Depression) report encloses the detailed analysis of Bipolar Disorder (Manic Depression) marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the Bipolar Disorder (Manic Depression) clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug, and the latest news and press releases.


Bipolar Disorder (Manic Depression) Approved Drugs


Vraylar/Cariprazine: Allergan (AbbVie)/Gedeon Richter

Vraylar is an oral capsule containing cariprazine as an active ingredient. It is approved in the US for schizophrenia, bipolar disorder, and Bipolar Disorder (Manic Depression). In the EU, it is approved as Reagila for the treatment of schizophrenia. Vraylar was discovered and co-developed by Gedeon Richter Plc and is licensed by Allergan in the US. Cariprazine is a dopamine-serotonin partial agonist. More specifically, cariprazine binds to D3 dopamine, D2 dopamine, and 5HT2B serotonin receptors with high potency and 5HT1A serotonin and 5HT2A serotonin receptors with moderate potency. Pharmacodynamic studies with cariprazine have shown that it acts as a partial agonist with a high binding affinity at dopamine D3, dopamine D2, and serotonin 5-HT1A receptors.


Latuda/Lurasidone Hydrochloride: Sunovion Pharmaceuticals (Sumitomo Dainippon Pharma)

Latuda is an oral tablet containing lurasidone hydrochloride as an active ingredient. It is approved in the US for Bipolar Disorder (Manic Depression) in pediatric patients (10–17 years of age) and schizophrenic patients (adolescent and adult); given as monotherapy and adjunctive therapy in adult patients with Bipolar Disorder (Manic Depression). In the EU, it is approved for the treatment of schizophrenia, whereas in Japan, it is approved for both, schizophrenia and bipolar disorder. Lurasidone is a benzothiazole-derivative, second-generation (atypical) antipsychotic. Like other atypical antipsychotics, it antagonizes dopamine D2 receptors and serotonin 5-HT2A and 5-HT7 receptors. It is a partial agonist at 5-HT1A receptors.

Note: Detailed Current therapies assessment will be provided in the full report of Bipolar Disorder (Manic Depression)


Bipolar Disorder (Manic Depression) Emerging Drugs


Lumateperone/ITI-007 (Intra-Cellular Therapies)

Lumateperone (ITI-007) is an investigational, first-in-class small molecule that provides selective and simultaneous modulation of serotonin, dopamine, and glutamate, three neurotransmitter pathways implicated in severe mental illness. It is a potent serotonin 5-HT2A receptor antagonist, a dopamine receptor phosphoprotein modulator (DPPM) acting as a presynaptic partial agonist and postsynaptic antagonist at dopamine D2 receptors, a dopamine D1 receptor-dependent indirect modulator of glutamate (both NDMA and AMPA), and a serotonin reuptake inhibitor. Currently, lumateperone is in Phase III clinical development as a novel treatment for Bipolar Disorder (Manic Depression). Lumateperone Bipolar Disorder (Manic Depression) clinical program consists of three monotherapy studies and one adjunctive study. The company submitted the sNDA to the US FDA in February 2021, and if approved, this drug would be the first therapy indicated for the treatment of depressive episodes associated with bipolar I or II disorder both as monotherapy and as adjunctive therapy in adults


NRX-100/NRX-101 (NeuroRx)

NeuroRx is developing a sequential therapy consisting of intravenous NRX-100 (ketamine HCL) for rapid stabilization of symptoms of depression and suicidal ideation followed by oral NRX-101 (fixed-dose combination of D-cycloserine and lurasidone) for maintenance of stabilization from symptoms of depression and suicidal ideation. NRX-101 is a proprietary, oral fixed-dose combination of two FDA-approved drugs: D-cycloserine, an NMDA receptor modulator; and Lurasidone (Latuda), a 5-HT2a receptor antagonist. NRX-101’s proprietary dual-mechanism of action targets the NMDA and 5-HT2a receptors – two key receptors in the brain. Currently, the molecule is under investigation in Phase III clinical trial for rapid stabilization of acute suicidal ideation and behavior in patients with Bipolar Disorder (Manic Depression). Additionally, the company is also initiating a Phase IIb/III clinical trial of NRX-100/NRX-101 to treat Bipolar Disorder (Manic Depression) in patients with ASIB. In September 2017, the US FDA granted fast track designation to NRX-100 (ketamine HCl) followed by NRX-101 (D-cycloserine + lurasidone) for Bipolar Disorder (Manic Depression) with suicidal ideation.


SEP-4199 (Sunovion/Sumitomo Dainippon Pharma)

SEP-4199 is a nonracemic ratio of amisulpride enantiomers with the potential to be the first benzamide treatment available in the US for mood disorders. Sunovion discovered that the pharmacology of amisulpride is enantiomer-specific and that increasing the ratio of R-amisulpride to S-amisulpride increases the potency for serotonin 5-HT7 receptors relative to dopamine D2 receptors. SEP-4199 was designed to increase levels of serotonin 5-HT7 activity intended to enhance antidepressant efficacy and produce reduced levels of D2 receptor occupancy appropriate for the treatment of Bipolar Disorder (Manic Depression). The pharmacological effect of SEP-4199 is distinct from racemic amisulpride, which is approved in several countries outside the US for the treatment of schizophrenia and other psychiatric condition.


Brexpiprazole (Lundbeck/Otsuka Pharmaceutical)

Brexpiprazole is a molecule discovered by Otsuka and co-developed by Otsuka and Lundbeck. Brexpiprazole is an atypical antipsychotic agent with a partial dopamine receptor D2 agonist effect. It is a partial agonist at dopamine D2 receptors designed to have a similar binding affinity to dopamine and serotonin receptors. The efficacy of brexpiprazole may be mediated through a combination of partial agonist activity at serotonin 5-HT1A and dopamine D2 receptors, and antagonist activity at serotonin 5-HT2A receptors. Brexpiprazole exhibits high affinity (subnanomolar) for these receptors as well as for noradrenaline alpha1B/2C receptors.

Note: Detailed emerging therapies assessment will be provided in the final report.

Bipolar Disorder (Manic Depression) Market Outlook

BD is a chronic mental health condition that can affect individuals of all ages and is characterized by potentially debilitating severe mood swings, including periods of depression and mania. BD refers to its depressive phase when symptomatic and depressive symptoms affect patients more commonly than manic symptoms. The symptoms include depressed mood, loss of interest or pleasure in activities, significant weight loss, insomnia, fatigue, feelings of worthlessness, diminished ability to concentrate, and recurrent thoughts of death or suicide attempt. Certain factors such as genetics, environment, brain structure, periods of high stress, and drug abuse can increase the risk of developing BD. Treatment of BD generally begins with the goal of bringing a patient to symptomatic recovery and stable mood. Once stable, the goal progresses to the reduction of subthreshold symptoms and relapse prevention. Currently, antipsychotics are the cornerstone in the treatment of Bipolar Disorder (Manic Depression). Although patients with BD spend more time in depression than in mania or hypomania, only four medications, all antipsychotics, have been approved by the US FDA. The olanzapine–fluoxetine combination (OFC) was first approved in 2003; Quetiapine was approved in 2006. In 2013, lurasidone was approved as a monotherapy and adjunct to ongoing lithium or valproate for bipolar I depression. The fourth, cariprazine, a new second-generation antipsychotic (SGA), was approved in 2019. Cariprazine joins quetiapine as the second SGA that is FDA-approved for both mania and depression, but it has significant advantages in metabolic side effects over quetiapine. Therapies approved in the 7MM include Vraylar (Cariprazine) and Latuda (Lurasidone Hydrochloride), among others.


At present, some companies have initiated clinical trials that investigate new treatment options. Key players such as Intra-Cellular Therapies (Caplyta, also known as Lumateperone), NeuroRx (NRX-100/NRX-101), Sunovion (Sumitomo Dainippon Pharma) (SEP-4199), Lundbeck/Otsuka Pharmaceutical (Rexulti/Rxulti, also known as Brexpiprazole), COMPASS Pathways (COMP 360, also known as Psilocybin therapy), Celon Pharma (Falkieri), and several others are investigating their candidates for the management of Bipolar Disorder (Manic Depression) in the 7MM.


Key Findings

The Bipolar Disorder (Manic Depression) market size in the 7MM is expected to change during the study period 2017–2030. The therapeutic market of Bipolar Disorder (Manic Depression) in the seven major markets is expected to increase during the study period (2017–2030) with a CAGR of 11.9%. According to the estimates, the highest market size of Bipolar Disorder (Manic Depression) is found in the United States followed by Germany.


The United States Market Outlook

The total market size of Bipolar Disorder (Manic Depression) therapies in the United States is expected to increase with a CAGR of 11.6% in the study period (2017–2030).


EU-5 Countries: Market Outlook

The total market size of Bipolar Disorder (Manic Depression) therapies in EU-5 countries is expected to increase with a CAGR of 13.4% in the study period (2017–2030).


Japan Market Outlook

The total market size of Bipolar Disorder (Manic Depression) therapies in Japan is expected to increase with a CAGR of 11.5% in the study period (2017–2030).

Bipolar Disorder (Manic Depression) Pipeline Development Activities

The drugs which are in pipeline include:


1. Lumateperone/ITI-007 (Intra-Cellular Therapies)

2. NRX-100/NRX-101 (NeuroRx)

3. SEP-4199 (Sunovion/Sumitomo Dainippon Pharma)

4. Brexpiprazole (Lundbeck/Otsuka Pharmaceutical)

5. Falkieri (Celon Pharma)

6. Psilocybin (COMPASS Pathways)


Note: Detailed emerging therapies assessment will be provided in the final report.

Analyst Commentary

  • Currently, antipsychotics are the cornerstone in the treatment of Bipolar Disorder (Manic Depression). Although patients with BD spend more time in depression than in mania or hypomania, only four medications, all antipsychotics, have been approved by the US FDA.
  • If compared to all the emerging therapies, Lumateperone/ITI-007, NRX-100/NRX-101, and Falkieri will going to have a major influence on the market size of Bipolar Disorder (Manic Depression) in the 7MM. Lumateperone/ITI-007 is expected to garner the highest market share.
  • Bipolar Disorder (Manic Depression) poses a therapeutic challenge, complicated by the need to relieve depressive symptoms without precipitating mania, hypomania, or worsening cycle frequency. Despite its high prevalence and clinical importance, there have been relatively few randomized controlled trials (RCTs) in Bipolar Disorder (Manic Depression) until recently. Although there are a limited number of established treatments demonstrating efficacy in acute episodes, there is a lack of evidence to decide between different agents. The therapeutic, prophylactic, or harmful effects in the long term are less well evaluated.

Access and Reimbursement Scenario in Bipolar Disorder (Manic Depression) Therapies

Patients with Bipolar Disorder (Manic Depression) often receive antidepressants during depressive episodes and as a component of maintenance treatment. Recent prescription data indicate that between 42% and 64% of BPD patients receive traditional mood stabilizers (e.g., lithium, valproic acid, carbamazepine), and 44–60% receive antipsychotic augmentation therapy. This increased utilization of antipsychotics is due to their antimanic or mood‐stabilizing properties and their more favorable tolerability profiles compared with conventional agents.


In addition, antipsychotic medications share several characteristics with antidepressants, i.e., serotonin (5‐HT) and norepinephrine reuptake inhibitors and 5HT‐1 A receptor agonism. Finally, recent clinical trials indicate that antipsychotic augmentation might also be efficacious for treating Bipolar Disorder (Manic Depression).


BD treatment accounted for 30% of costs, and comorbid disorders for 70% of treatment costs. Inpatient care (35%), outpatient care (16%), prescriptions (13%), and physician encounters (11%) were the key cost components. Patients with BD received various medications: lithium, 13%; anticonvulsants, 35%; second-generation antipsychotics, 24%; first-generation antipsychotics, 22%; and antidepressants, 42%.


Seroquel is covered under Medicare Part D and Medicare Advantage plans. In the deductible stage, the price of quetiapine will be between USD 4 million and USD 124 million, and in the copay stage, it will be USD 46 million. New York State Medicaid Fee-for-Service Pharmacy Programs cover Seroquel. By using AstraZeneca’s saving card, eligible commercially insured patients will pay USD 3 million per 30-day supply, subject to a maximum savings of USD 185 million per 30-day supply. Uninsured patients will receive up to USD 185 million in savings on out-of-pocket costs that exceed USD 3 million per 30-day supply of Seroquel XR.

Note: Detailed HTA assessment will be provided in the final report.

KOL-Views

To keep up with current market trends, we take KOLs and SME’s opinions working in the Bipolar Disorder (Manic Depression) domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or Bipolar Disorder (Manic Depression) market trends. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.

Competitive Intelligence Analysis

We perform Competitive and Market Intelligence analysis of the Bipolar Disorder (Manic Depression) Market by using various Competitive Intelligence tools that includes – SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report

  • The report covers the descriptive overview of Bipolar Disorder (Manic Depression), explaining its causes, signs and symptoms, pathophysiology, and currently available therapies.
  • Comprehensive insight has been provided into the Bipolar Disorder (Manic Depression) epidemiology and treatment in the 7MM.
  • Additionally, an all-inclusive account of both the current and emerging therapies for Bipolar Disorder (Manic Depression) is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape.
  • A detailed review of the Bipolar Disorder (Manic Depression) market; historical and forecasted is included in the report, covering drug outreach in the 7MM.
  • The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Bipolar Disorder (Manic Depression) market.

Report Highlights

  • In the coming years, the Bipolar Disorder (Manic Depression) market is set to change due to the rising awareness of the disease and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
  • The companies and academics are working to assess challenges and seek opportunities that could influence Bipolar Disorder (Manic Depression) R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
  • Major players are involved in developing therapies for Bipolar Disorder (Manic Depression). The launch of emerging therapies will significantly impact the Bipolar Disorder (Manic Depression) market.
  • A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Bipolar Disorder (Manic Depression).
  • Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends, and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.

Bipolar Disorder (Manic Depression) Report Insights

  • Patient Population
  • Therapeutic Approaches
  • Bipolar Disorder (Manic Depression) Pipeline Analysis
  • Bipolar Disorder (Manic Depression) Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies

Bipolar Disorder (Manic Depression) Report Key Strengths

  • 11 Years Forecast
  • 7MM Coverage
  • Bipolar Disorder (Manic Depression) Epidemiology Segmentation
  • Key Cross Competition
  • Highly Analyzed Market
  • Drugs Uptake

Bipolar Disorder (Manic Depression) Report Assessment

  • SWOT Analysis
  • Current Treatment Practices
  • Unmet Needs
  • Pipeline Product Profiles
  • Conjoint Analysis
  • Market Attractiveness
  • Market Drivers and Barriers

Key Questions

Market Insights:

  • What was the Bipolar Disorder (Manic Depression) Market share (%) distribution in 2017 and how it would look like in 2030?
  • What would be the Bipolar Disorder (Manic Depression) total market size as well as market size by therapies across the 7MM during the study period (2017–2030)?
  • What are the key findings of the market across the 7MM and which country will have the largest Bipolar Disorder (Manic Depression) market size during the study period (2017–2030)?
  • At what CAGR, the Bipolar Disorder (Manic Depression) market is expected to grow in the 7MM during the study period (2017–2030)?
  • What would be the Bipolar Disorder (Manic Depression) market outlook across the 7MM during the study period (2017–2030)?
  • What would be the Bipolar Disorder (Manic Depression) market growth till 2030 and what will be the resultant market size in the year 2030?
  • How would the market drivers, barriers, and future opportunities affect the market dynamics and subsequent analysis of the associated trends?
  • Bipolar Disorder (Manic Depression) patient types/pool where unmet need is more and whether emerging therapies will be able to address the residual unmet need?
  • How emerging therapies are performing on the parameters like efficacy, safety, route of administration (RoA), treatment duration, and frequencies based on their clinical trial results?
  • Among the emerging therapies, what are the potential therapies which are expected to disrupt the Bipolar Disorder (Manic Depression) market?


Epidemiology Insights:

  • What are the disease risks, burdens, and unmet needs of the Bipolar Disorder (Manic Depression)?
  • What is the historical Bipolar Disorder (Manic Depression) patient pool in the seven major markets covering the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
  • What would be the forecasted patient pool of Bipolar Disorder (Manic Depression) in the 7 major markets covering the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
  • What will be the growth opportunities in the 7MM concerning the patient population about Bipolar Disorder (Manic Depression)?
  • Out of all the 7MM countries, which country would have the highest prevalent population of Bipolar Disorder (Manic Depression) during the study period (2017–2030)?
  • At what CAGR the population is expected to grow in the 7MM during the study period (2017–2030)?
  • What are the various recent and upcoming events which are expected to improve the diagnosis of Bipolar Disorder (Manic Depression)?


Current Treatment Scenario and Emerging Therapies:

  • What are the current options for the treatment of Bipolar Disorder (Manic Depression)?
  • What are the current treatment guidelines for the treatment of Bipolar Disorder (Manic Depression) in the US, Europe, and Japan?
  • How many companies are developing therapies for the treatment of Bipolar Disorder (Manic Depression)?
  • How many therapies are developed by each company for the treatment of Bipolar Disorder (Manic Depression)?
  • How many emerging therapies are in the mid-stage and late stages of development for the treatment of Bipolar Disorder (Manic Depression)?
  • What are the key collaborations (Industry–Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Bipolar Disorder (Manic Depression) therapies?
  • What are the recent novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Bipolar Disorder (Manic Depression) and their status?
  • What are the key designations that have been granted for the emerging therapies for Bipolar Disorder (Manic Depression)?
  • What is the global historical and forecasted market of Bipolar Disorder (Manic Depression)?

Reasons to buy

  • The report will help in developing business strategies by understanding trends shaping and driving the Bipolar Disorder (Manic Depression) market.
  • To understand the future market competition in the Bipolar Disorder (Manic Depression) market and an Insightful review of the key market drivers and barriers.
  • Organize sales and marketing efforts by identifying the best opportunities for Bipolar Disorder (Manic Depression) in the US, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
  • Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors.
  • Organize sales and marketing efforts by identifying the best opportunities for the Bipolar Disorder (Manic Depression) market.
  • To understand the future market competition in the Bipolar Disorder (Manic Depression) market.

1. Key Insights

2. Report Introduction

3. Bipolar Disorder (Manic Depression) Market Overview at a Glance

3.1. Market Share (%) Distribution of Bipolar Disorder (Manic Depression) in 2017

3.2. Market Share (%) Distribution of Bipolar Disorder (Manic Depression) in 2030

4. Executive Summary of Bipolar Disorder (Manic Depression)

5. Epidemiology and Market Methodology

6. Disease Background and Overview

6.1. Introduction

6.2. Difference between Bipolar and Unipolar Depression

6.3. Classification of BD According to DSM-5

6.4. Signs and symptoms

6.5. Causes

6.6. Risk Factors

6.7. Pathophysiology

6.8. Genetic Findings in BD

6.9. Biomarkers

7. Diagnosis of Bipolar Disorder

7.1. Diagnostic criteria for major forms of BD

7.1.1. Diagnosis to rule out thyroid disorders

7.2. Differential Diagnosis

7.3. Diagnostic Guidelines

7.3.1. Evidence-based guidelines for treating bipolar disorder: Revised third edition recommendations from the British Association for Psychopharmacology Guidelines

7.3.2. The National Institute for Health and Care Excellence (NICE) guidelines for the diagnosis of the bipolar disorder

8. Current Treatment Practices of Bipolar Disorder

8.1. Treatment of Bipolar Disorder

8.1.1. Treatment Algorithm

8.2. Treatment Guidelines

8.2.1. The World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Bipolar Disorders: Update 2010 on the treatment of acute Bipolar Disorder (Manic Depression)

8.2.2. The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders: update 2012 on the long-term treatment of the bipolar disorder

8.2.3. The American Psychiatric Association Practice Guideline for the Treatment of Bipolar Disorder

8.2.4. The National Institute for Health and Care Excellence (NICE) guidelines for the treatment of the bipolar disorder

8.2.5. Evidence-based guidelines for treating bipolar disorder: Revised third edition recommendations from the British Association for Psychopharmacology

8.2.6. Guideline for the treatment of bipolar disorder by the Japanese Society of Mood Disorders, 2012

8.2.7. International Society for Bipolar Disorders Clinical (ISBD) Recommendations for Antidepressant Use in Bipolar Disorders

8.2.8. The International College of Neuro-psychopharmacology (CINP) Treatment Guidelines for Bipolar Disorder in Adults (CINP-BD-2017)

8.3. Comparison of Bipolar disorder guidelines

9. Epidemiology and Patient Population

9.1. Key Findings

9.2. Epidemiology of Bipolar Disorder (Manic Depression)

9.3. Epidemiology Scenario: 7MM

9.3.1. Total Diagnosed Prevalent Cases of Bipolar Disorder (Manic Depression)

9.3.2. Type-specific Diagnosed Prevalent Cases of Bipolar Disorder (Manic Depression)

9.3.3. Severity-specific Diagnosed Prevalent Cases of Bipolar Disorder (Manic Depression)

9.3.4. Total Treated Cases of Bipolar Disorder (Manic Depression)

10. The United States

10.1. Total Diagnosed Prevalent Cases of Bipolar Disorder (Manic Depression)

10.2. Type-specific Diagnosed Prevalent Cases of Bipolar Disorder (Manic Depression)

10.3. Severity-specific Diagnosed Prevalent Cases of Bipolar Disorder (Manic Depression)

10.4. Total Treated Cases of Bipolar Disorder (Manic Depression)

11. EU-5

11.1. Germany

11.1.1. Total Diagnosed Prevalent Cases of Bipolar Disorder (Manic Depression)

11.1.2. Type-specific Diagnosed Prevalent Cases of Bipolar Disorder (Manic Depression)

11.1.3. Severity-specific Diagnosed Prevalent Cases of Bipolar Disorder (Manic Depression)

11.1.4. Total Treated Cases of Bipolar Disorder (Manic Depression)

11.2. France

11.2.1. Total Diagnosed Prevalent Cases of Bipolar Disorder (Manic Depression)

11.2.2. Type-specific Diagnosed Prevalent Cases of Bipolar Disorder (Manic Depression)

11.2.3. Severity-specific Diagnosed Prevalent Cases of Bipolar Disorder (Manic Depression)

11.2.4. Total Treated Cases of Bipolar Disorder (Manic Depression)

11.3. Italy

11.3.1. Total Diagnosed Prevalent Cases of Bipolar Disorder (Manic Depression)

11.3.2. Type-specific Diagnosed Prevalent Cases of Bipolar Disorder (Manic Depression)

11.3.3. Severity-specific Diagnosed Prevalent Cases of Bipolar Disorder (Manic Depression)

11.3.4. Total Treated Cases of Bipolar Disorder (Manic Depression)

11.4. Spain

11.4.1. Total Diagnosed Prevalent Cases of Bipolar Disorder (Manic Depression)

11.4.2. Type-specific Diagnosed Prevalent Cases of Bipolar Disorder (Manic Depression)

11.4.3. Severity-specific Diagnosed Prevalent Cases of Bipolar Disorder (Manic Depression)

11.4.4. Total Treated Cases of Bipolar Disorder (Manic Depression)

11.5. The United Kingdom

11.5.1. Total Diagnosed Prevalent Cases of Bipolar Disorder (Manic Depression)

11.5.2. Type-specific Diagnosed Prevalent Cases of Bipolar Disorder (Manic Depression)

11.5.3. Severity-specific Diagnosed Prevalent Cases of Bipolar Disorder (Manic Depression)

11.5.4. Total Treated Cases of Bipolar Disorder (Manic Depression)

12. Japan

12.1. Total Diagnosed Prevalent Cases of Bipolar Disorder (Manic Depression)

12.2. Type-specific Diagnosed Prevalent Cases of Bipolar Disorder (Manic Depression)

12.3. Severity-specific Diagnosed Prevalent Cases of Bipolar Disorder (Manic Depression)

12.4. Total Treated Cases of Bipolar Disorder (Manic Depression)

13. Patient Journey

14. Key Endpoints in Bipolar Disorder (Manic Depression) Clinical Trials

15. Marketed Therapies

15.1. Vraylar (Cariprazine): Allergan (AbbVie)/Gedeon Richter

15.1.1. Drug Description

15.1.2. Regulatory Milestones

15.1.3. Other Developmental Activities

15.1.4. Pivotal Clinical Trial

15.1.5. Ongoing Current Pipeline Activity

15.2. Latuda (Lurasidone Hydrochloride): Sunovion Pharmaceuticals (Sumitomo Dainippon Pharma)

15.2.1. Drug Description

15.2.2. Regulatory Milestones

15.2.3. Other Developmental Activities

15.2.4. Pivotal Clinical Trial

16. Emerging Therapies

16.1. Caplyta (ITI-007; Lumateperone): Intra-Cellular Therapies

16.1.1. Product Description

16.1.2. Other Developmental Activities

16.1.3. Clinical Development

16.1.4. Safety and Efficacy

16.2. NRX-100/NRX-101: NeuroRx

16.2.1. Product Description

16.2.2. Other Developmental Activities

16.2.3. Clinical Development

16.2.4. Safety and Efficacy

16.3. SEP-4199: Sunovion (Sumitomo Dainippon Pharma)

16.3.1. Product Description

16.3.2. Other Developmental Activities

16.3.3. Clinical Development

16.3.4. Safety and Efficacy

16.4. Rexulti/Rxulti (Brexpiprazole): Lundbeck/Otsuka Pharmaceutical

16.4.1. Product Description

16.4.2. Other Developmental Activities

16.4.3. Clinical Development

16.4.4. Safety and Efficacy

16.5. Falkieri (Esketamine): Celon Pharma

16.5.1. Product Description

16.5.2. Other Developmental Activities

16.5.3. Clinical Development

16.5.4. Safety and Efficacy

16.6. COMP 360 (Psilocybin): COMPASS Pathways

16.6.1. Product Description

16.6.2. Other Developmental Activities

16.6.3. Clinical Development

17. Bipolar Disorder (Manic Depression): 7 Major Market Analysis

17.1. Key Findings

17.2. Market Outlook

17.3. 7MM Market Size

17.3.1. Total Market Size of Bipolar Disorder (Manic Depression) in the 7MM

17.3.2. Market Size of Bipolar Disorder (Manic Depression) by Therapies in the 7MM

18. The United States Market Size

18.1. Total Market Size of Bipolar Disorder (Manic Depression) in the United States

18.2. Market Size of Bipolar Disorder (Manic Depression) by Therapies in the United States

19. EU-5 Market Size

19.1. Germany

19.1.1. Total Market size of Bipolar Disorder (Manic Depression) in Germany

19.1.2. Market Size of Bipolar Disorder (Manic Depression) by Therapies in Germany

19.2. France

19.2.1. Total Market size of Bipolar Disorder (Manic Depression) in France

19.2.2. Market Size of Bipolar Disorder (Manic Depression) by Therapies in France

19.3. Italy

19.3.1. Total Market size of Bipolar Disorder (Manic Depression) in Italy

19.3.2. Market Size of Bipolar Disorder (Manic Depression) by Therapies in Italy

19.4. Spain

19.4.1. Total Market size of Bipolar Disorder (Manic Depression) in Spain

19.4.2. Market Size of Bipolar Disorder (Manic Depression) by Therapies in Spain

19.5. The United Kingdom

19.5.1. Total Market size of Bipolar Disorder (Manic Depression) in the United Kingdom

19.5.2. Market Size of Bipolar Disorder (Manic Depression) by Therapies in the United Kingdom

20. Japan

20.1. Total Market size of Bipolar Disorder (Manic Depression) in Japan

20.2. Market Size of Bipolar Disorder (Manic Depression) by Therapies in Japan

21. Market Access and Reimbursement

21.1. Key HTA decisions for Bipolar Disorder (Manic Depression)

21.2. Patient Access Programs

22. Market Drivers

23. Market Barriers

24. SWOT Analysis

25. Unmet Needs

26. Appendix

26.1. Bibliography

26.2. Report Methodology

27. DelveInsight Capabilities

28. Disclaimer

29. About DelveInsight

List of Table

Table 1: Summary of Bipolar Disorder (Manic Depression), Market, Epidemiology, and Key Events (2017–2030)

Table 2: Symptoms associated with manic and depressive episodes

Table 3: Genome-wide association study findings in BD

Table 4: Main findings of circulating biomarkers in BD

Table 5: Agents approved by the US FDA for acute bipolar mania, Bipolar Disorder (Manic Depression), and maintenance

Table 6: Categories of evidence (CE) and grade of recommendation (RG) for pharmacological and physical treatments used in acute Bipolar I depression (in alphabetical order within one category of evidence)

Table 7: Overall Recommendation Grades for long-term treatment

Table 8: Comparison of guidelines

Table 9: Total Diagnosed Prevalent Cases of Bipolar Disorder (Manic Depression) in the 7MM (2017–2030)

Table 10: Type-specific Diagnosed Prevalent Cases of Bipolar Disorder (Manic Depression) in the 7MM (2017–2030)

Table 11: Severity-specific Diagnosed Prevalent Cases of Bipolar Disorder (Manic Depression) in the 7MM (2017–2030)

Table 12: Total Treated Cases of Bipolar Disorder (Manic Depression) in the 7MM (2017–2030)

Table 13: Total Diagnosed Prevalent Cases of Bipolar Disorder (Manic Depression) in the United States (2017–2030)

Table 14: Type-specific Diagnosed Prevalent Cases of Bipolar Disorder (Manic Depression) in the United States (2017–2030)

Table 15: Severity-specific Diagnosed Prevalent Cases of Bipolar Disorder (Manic Depression) in the United States (2017–2030)

Table 16: Total Treated Cases of Bipolar Disorder (Manic Depression) in the United States (2017–2030)

Table 17: Total Diagnosed Prevalent Cases of Bipolar Disorder (Manic Depression) in Germany (2017–2030)

Table 18: Type-specific Diagnosed Prevalent Cases of Bipolar Disorder (Manic Depression) in Germany (2017–2030)

Table 19: Severity-specific Diagnosed Prevalent Cases of Bipolar Disorder (Manic Depression) in Germany (2017–2030)

Table 20: Total Treated Cases of Bipolar Disorder (Manic Depression) in Germany (2017–2030)

Table 21: Total Diagnosed Prevalent Cases of Bipolar Disorder (Manic Depression) in France (2017–2030)

Table 22: Type-specific Diagnosed Prevalent Cases of Bipolar Disorder (Manic Depression) in France (2017–2030)

Table 23: Severity-specific Diagnosed Prevalent Cases of Bipolar Disorder (Manic Depression) in France (2017–2030)

Table 24: Total Treated Cases of Bipolar Disorder (Manic Depression) in France (2017–2030)

Table 25: Total Diagnosed Prevalent Cases of Bipolar Disorder (Manic Depression) in Italy (2017–2030)

Table 26: Type-specific Diagnosed Prevalent Cases of Bipolar Disorder (Manic Depression) in Italy (2017–2030)

Table 27: Severity-specific Diagnosed Prevalent Cases of Bipolar Disorder (Manic Depression) in Italy (2017–2030)

Table 28: Total Treated Cases of Bipolar Disorder (Manic Depression) in Italy (2017–2030)

Table 29: Total Diagnosed Prevalent Cases of Bipolar Disorder (Manic Depression) in Spain (2017–2030)

Table 30: Type-specific Diagnosed Prevalent Cases of Bipolar Disorder (Manic Depression) in Spain (2017–2030)

Table 31: Severity-specific Diagnosed Prevalent Cases of Bipolar Disorder (Manic Depression) in Spain (2017–2030)

Table 32: Total Treated Cases of Bipolar Disorder (Manic Depression) in Spain (2017–2030)

Table 33: Total Diagnosed Prevalent Cases of Bipolar Disorder (Manic Depression) in the United Kingdom (2017–2030)

Table 34: Type-specific Diagnosed Prevalent Cases of Bipolar Disorder (Manic Depression) in the United Kingdom (2017–2030)

Table 35: Severity-specific Diagnosed Prevalent Cases of Bipolar Disorder (Manic Depression) in the United Kingdom (2017–2030)

Table 36: Total Treated Cases of Bipolar Disorder (Manic Depression) in the United Kingdom (2017–2030)

Table 37: Total Diagnosed Prevalent Cases of Bipolar Disorder (Manic Depression) in Japan (2017–2030)

Table 38: Type-specific Diagnosed Prevalent Cases of Bipolar Disorder (Manic Depression) in Japan (2017–2030)

Table 39: Severity-specific Diagnosed Prevalent Cases of Bipolar Disorder (Manic Depression) in Japan (2017–2030)

Table 40: Total Treated Cases of Bipolar Disorder (Manic Depression) in Japan (2017–2030)

Table 41: Vraylar (Cariprazine), Clinical Trial Description, 2021

Table 42: Caplyta (ITI-007; Lumateperone), Clinical Trial Description, 2021

Table 43: NRX-100/NRX-101, Clinical Trial Description, 2021

Table 44: SEP-4199, Clinical Trial Description, 2021

Table 45: Rexulti/Rxulti (Brexpiprazole), Clinical Trial Description, 2021

Table 46: Falkieri (Esketamine), Clinical Trial Description, 2021

Table 47: COMP 360 (Psilocybin), Clinical Trial Description, 2021

Table 48: 7MM Market Size of Bipolar Disorder (Manic Depression) in USD Million (2017–2030)

Table 49: 7MM Market Size of Bipolar Disorder (Manic Depression) by Therapies in USD Million (2017–2030)

Table 50: The United States Market Size of Bipolar Disorder (Manic Depression) in USD Million (2017–2030)

Table 51: The United States Market Size of Bipolar Disorder (Manic Depression) by Therapies in USD Million (2017–2030)

Table 52: Germany Market Size of Bipolar Disorder (Manic Depression) in USD Million (2017–2030)

Table 53: Germany Market Size of Bipolar Disorder (Manic Depression) by Therapies in USD Million (2017–2030)

Table 54: France Market Size of Bipolar Disorder (Manic Depression) in USD Million (2017–2030)

Table 55: France Market Size of Bipolar Disorder (Manic Depression) by Therapies in USD Million (2017–2030)

Table 56: Italy Market Size of Bipolar Disorder (Manic Depression) in USD Million (2017–2030)

Table 57: Italy Market Size of Bipolar Disorder (Manic Depression) by Therapies in USD Million (2017–2030)

Table 58: Spain Market Size of Bipolar Disorder (Manic Depression) in USD Million (2017–2030)

Table 59: Spain Market Size of Bipolar Disorder (Manic Depression) by Therapies in USD Million (2017–2030)

Table 60: The United Kingdom Market Size of Bipolar Disorder (Manic Depression) in USD Million (2017–2030)

Table 61: The United Kingdom Market Size of Bipolar Disorder (Manic Depression) by Therapies in USD Million (2017–2030)

Table 62: Japan Market Size of Bipolar Disorder (Manic Depression) in USD Million (2017–2030)

Table 63: Japan Market Size of Bipolar Disorder (Manic Depression) by Therapies in USD Million (2017–2030)

Table 64: Key HTA Decisions

List of Figures

Figure 1: Epidemiology and Market Methodology

Figure 2: Symptoms with potential diagnostic utility in bipolar and unipolar depression

Figure 3: Main subtypes of BD

Figure 4: Symptoms of BD

Figure 5: Effects of BD on the body

Figure 6: Causes of BD

Figure 7: Triggers in BD

Figure 8: Pathophysiological mechanisms of BD

Figure 9: Multifactorial model of BD

Figure 10: Algorithm for the Treatment of Mania/Hypomania

Figure 11: Algorithm for the Treatment of Depression in BD

Figure 12: Psychopharmacology Algorithm

Figure 13: Total Diagnosed Prevalent Cases of Bipolar Disorder (Manic Depression) in the 7MM (2017–2030)

Figure 14: Type-specific Diagnosed Prevalent Cases of Bipolar Disorder (Manic Depression) in the 7MM (2017–2030)

Figure 15: Severity-specific Diagnosed Prevalent Cases of Bipolar Disorder (Manic Depression) in the 7MM (2017–2030)

Figure 16: Total Treated Cases of Bipolar Disorder (Manic Depression) in the 7MM (2017–2030)

Figure 17: Total Diagnosed Prevalent Cases of Bipolar Disorder (Manic Depression) in the United States (2017–2030)

Figure 18: Type-specific Diagnosed Prevalent Cases of Bipolar Disorder (Manic Depression) in the United States (2017–2030)

Figure 19: Severity-specific Diagnosed Prevalent Cases of Bipolar Disorder (Manic Depression) in the United States (2017–2030)

Figure 20: Total Treated Cases of Bipolar Disorder (Manic Depression) in the United States (2017–2030)

Figure 21: Total Diagnosed Prevalent Cases of Bipolar Disorder (Manic Depression) in Germany (2017–2030)

Figure 22: Type-specific Diagnosed Prevalent Cases of Bipolar Disorder (Manic Depression) in Germany (2017–2030)

Figure 23: Severity-specific Diagnosed Prevalent Cases of Bipolar Disorder (Manic Depression) in Germany (2017–2030)

Figure 24: Total Treated Cases of Bipolar Disorder (Manic Depression) in Germany (2017–2030)

Figure 25: Total Diagnosed Prevalent Cases of Bipolar Disorder (Manic Depression) in France (2017–2030)

Figure 26: Type-specific Diagnosed Prevalent Cases of Bipolar Disorder (Manic Depression) in France (2017–2030)

Figure 27: Severity-specific Diagnosed Prevalent Cases of Bipolar Disorder (Manic Depression) in France (2017–2030)

Figure 28: Total Treated Cases of Bipolar Disorder (Manic Depression) in France (2017–2030)

Figure 29: Total Diagnosed Prevalent Cases of Bipolar Disorder (Manic Depression) in Italy (2017–2030)

Figure 30: Type-specific Diagnosed Prevalent Cases of Bipolar Disorder (Manic Depression) in Italy (2017–2030)

Figure 31: Severity-specific Diagnosed Prevalent Cases of Bipolar Disorder (Manic Depression) in Italy (2017–2030)

Figure 32: Total Treated Cases of Bipolar Disorder (Manic Depression) in Italy (2017–2030)

Figure 33: Total Diagnosed Prevalent Cases of Bipolar Disorder (Manic Depression) in Spain (2017–2030)

Figure 34: Type-specific Diagnosed Prevalent Cases of Bipolar Disorder (Manic Depression) in Spain (2017–2030)

Figure 35: Severity-specific Diagnosed Prevalent Cases of Bipolar Disorder (Manic Depression) in Spain (2017–2030)

Figure 36: Total Treated Cases of Bipolar Disorder (Manic Depression) in Spain (2017–2030)

Figure 37: Total Diagnosed Prevalent Cases of Bipolar Disorder (Manic Depression) in the United Kingdom (2017–2030)

Figure 38: Type-specific Diagnosed Prevalent Cases of Bipolar Disorder (Manic Depression) in the United Kingdom (2017–2030)

Figure 39: Severity-specific Diagnosed Prevalent Cases of Bipolar Disorder (Manic Depression) in the United Kingdom (2017–2030)

Figure 40: Total Treated Cases of Bipolar Disorder (Manic Depression) in the United Kingdom (2017–2030)

Figure 41: Total Diagnosed Prevalent Cases of Bipolar Disorder (Manic Depression) in Japan (2017–2030)

Figure 42: Type-specific Diagnosed Prevalent Cases of Bipolar Disorder (Manic Depression) in Japan (2017–2030)

Figure 43: Severity-specific Diagnosed Prevalent Cases of Bipolar Disorder (Manic Depression) in Japan (2017–2030)

Figure 44: Total Treated Cases of Bipolar Disorder (Manic Depression) in Japan (2017–2030)

Figure 45: Market Size of Bipolar Disorder (Manic Depression) in the 7MM, USD Million (2017–2030)

Figure 46: 7MM Market Size of Bipolar Disorder (Manic Depression) by Therapies in USD Million (2017–2030)

Figure 47: Market Size of Bipolar Disorder (Manic Depression) in the United States, USD Million (2017–2030)

Figure 48: The United States Market Size of Bipolar Disorder (Manic Depression) by Therapies in USD Million (2017–2030)

Figure 49: Market Size of Bipolar Disorder (Manic Depression) in Germany, USD Million (2017–2030)

Figure 50: Germany Market Size of Bipolar Disorder (Manic Depression) by Therapies in USD Million (2017–2030)

Figure 51: Market Size of Bipolar Disorder (Manic Depression) in France, USD Million (2017–2030)

Figure 52: France Market Size of Bipolar Disorder (Manic Depression) by Therapies in USD Million (2017–2030)

Figure 53: Market Size of Bipolar Disorder (Manic Depression) in Italy, USD Million (2017–2030)

Figure 54: Italy Market Size of Bipolar Disorder (Manic Depression) by Therapies in USD Million (2017–2030)

Figure 55: Market Size of Bipolar Disorder (Manic Depression) in Spain, USD Million (2017–2030)

Figure 56: Spain Market Size of Bipolar Disorder (Manic Depression) by Therapies in USD Million (2017–2030)

Figure 57: Market Size of Bipolar Disorder (Manic Depression) in the United Kingdom, USD Million (2017–2030)

Figure 58: The United Kingdom Market Size of Bipolar Disorder (Manic Depression) by Therapies in USD Million (2017–2030)

Figure 59: Market Size of Bipolar Disorder (Manic Depression) in Japan, USD Million (2017–2030)

Figure 60: Japan Market Size of Bipolar Disorder (Manic Depression) by Therapies in USD Million (2017–2030)

Allergan (AbbVie)/Gedeon Richter

Sunovion Pharmaceuticals (Sumitomo Dainippon Pharma)

Intra-Cellular Therapies

NeuroRx

Sunovion (Sumitomo Dainippon Pharma)

Lundbeck/Otsuka Pharmaceutical

Celon Pharma

COMPASS Pathways

  • Tags:
  • Bipolar Disorder (Manic Depression)...
  • Bipolar Disorder (Manic Depression...
  • Bipolar Disorder (Manic Depression...
  • Bipolar Disorder (Manic Depression...
  • Bipolar Disorder (Manic Depression...
  • Bipolar Disorder (Manic Depression...
  • Bipolar Disorder (Manic Depression...
  • Bipolar Disorder (Manic Depression...
  • Bipolar Disorder (Manic Depression...
  • Bipolar Disorder (Manic Depression...
  • Bipolar Disorder (Manic Depression...
  • Bipolar Disorder (Manic Depression...
  • Bipolar Disorder (Manic Depression...
  • Bipolar Disorder (Manic Depression...

Forward to Friend

Need A Quote